Norah Terrault, MPH, MD

Hepatologist

Dr. Norah Terrault is a hepatologist or liver specialist who is recognized internationally for the treatment of viral hepatitis and liver transplantation. Her research includes the study of viral hepatitis and its progression and treatment, especially in liver transplant patients. Her research includes several clinical trials related to preventing and treating chronic hepatitis C and B. Her studies in this area have been presented to the American Association for the Study of Liver Diseases, the leading organization for research in liver disease.

Terrault completed medical training at the University of Alberta and specialty medical training in Internal Medicine and Gastroenterology at the University of Toronto, both in Canada. Her post-doctoral fellowship in hepatology and viral hepatitis was completed at the University of California, San Francisco while earning a concurrent master's degree in public health from the University of California at Berkeley. She joined the medical staff at UCSF Medical Center in 1997.

Clinics

Liver Disease and Liver Transplant
350 Parnassus Ave., Suite 300
San Francisco, CA 94143
Phone: (415) 353-2318
Fax: (415) 353-2407

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Conditions & Treatments

Academic Title

Professor

More about Norah Terrault

Education

University of Alberta School of Medicine 1987

Residencies

University of Toronto Health Network, Internal Medicine 1991

Fellowships

University of Toronto Health Network, Gastroenterology 1993
UCSF Medical Center, Gastroenterology 1995

Selected Research and Publications

  1. Lee BP, Terrault NA. Early liver transplantation for severe alcoholic hepatitis: moving from controversy to consensus. Curr Opin Organ Transplant. 2018 Jan 30.
  2. Ajmera V, Belt P, Wilson LA, Gill RM, Loomba R, Kleiner DE, Neuschwander-Tetri BA, Terrault N. Among Patients with Nonalcoholic Fatty Liver Disease, Modest Alcohol Use is Associated with Less Improvement in Histologic Steatosis and Steatohepatitis. Clin Gastroenterol Hepatol. 2018 Jan 25.
  3. Saxena V, Khungar V, Verna EC, Levitsky J, Brown RS, Hassan MA, Sulkowski MS, O'Leary JG, Koraishy F, Galati JS, Kuo AA, Vainorius M, Akushevich L, Nelson DR, Fried MW, Terrault N, Reddy KR. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology. 2017 Oct; 66(4):1090-1101.
  4. Radhakrishnan K, Chi A, Quan DJ, Roberts JP, Terrault NA. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. Transplantation. 2017 Sep; 101(9):2079-2082.
  5. VanWagner LB, Ning H, Allen NB, Ajmera V, Lewis CE, Carr JJ, Lloyd-Jones DM, Terrault NA, Siddique J. Alcohol Use and Cardiovascular Disease Risk in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology. 2017 Aug 09.
  6. Zhou K, Terrault N. Management of hepatitis B in special populations. Best Pract Res Clin Gastroenterol. 2017 Jun; 31(3):311-320.
  7. Levitsky J, Formica RN, Bloom RD, Charlton M, Curry M, Friedewald J, Friedman J, Goldberg D, Hall S, Ison M, Kaiser T, Klassen D, Klintmalm G, Kobashigawa J, Liapakis A, O'Conner K, Reese P, Stewart D, Terrault N, Theodoropoulos N, Trotter J, Verna E, Volk M. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017 May 29.
  8. Yoshida EM, Kwo P, Agarwal K, Duvoux C, Durand F, Peck-Radosavljevic M, Lilly L, Willems B, Vargas H, Kumar P, Brown RS, Horsmans Y, De-Oertel S, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault N, Rizzetto M, Müllhaupt B. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Ann Hepatol. 2017 May - Jun; 16(3):375-381.
  9. Ajmera VH, Terrault NA, Harrison SA. Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review. Hepatology. 2017 Jun; 65(6):2090-2099.
  10. Sarkar M, Wellons M, Cedars MI, VanWagner L, Gunderson EP, Ajmera V, Torchen L, Siscovick D, Carr JJ, Terry JG, Rinella M, Lewis CE, Terrault N. Testosterone Levels in Pre-Menopausal Women are Associated With Nonalcoholic Fatty Liver Disease in Midlife. Am J Gastroenterol. 2017 May; 112(5):755-762.
  11. Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, Younossi Z. Hepatitis C virus infection. Nat Rev Dis Primers. 2017 Mar 02; 3:17006.
  12. Terrault NA, McCaughan GW, Curry MP, Gane E, Fagiuoli S, Fung J, Agarwal K, Lilly L, Strasser SI, Brown K, Gadano A, Kwo PY, Burra P, Samuel D, Charlton M, Pessoa MG, Berenguer M. International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT CANDIDATES. Transplantation. 2017 Mar 01.
  13. Terrault N, Berenguer M, Strasser S, Gadano A, Lilly L, Samuel D, Kwo PY, Agarwal K, Curry M, Fagiuoli S, Fung JY, Gane E, Brown KA, Burra P, Charlton M, Pessoa M, McCaughan GW. International Liver Transplant Society Consensus Statement on HEPATITIS C MANAGEMENT IN LIVER TRANSPLANT RECIPIENTS. Transplantation. 2017 Mar 01.
  14. Walsh CE, Workowski K, Terrault NA, Sax PE, Cohen A, Bowlus CL, Kim AY, Hyland RH, Han B, Wang J, Stamm LM, Brainard DM, McHutchison JG, von Drygalski A, Rhame F, Fried MW, Kouides P, Balba G, Reddy KR. Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders. Haemophilia. 2017 Mar; 23(2):198-206.
  15. Butt Z, Dew MA, Liu Q, Simpson MA, Smith AR, Zee J, Gillespie BW, Abbey SE, Ladner DP, Weinrieb R, Fisher RA, Hafliger S, Terrault N, Burton J, Sherker AH, DiMartini A. Psychological Outcomes of Living Liver Donors From a Multicenter Prospective Study: Results From the Adult-to-Adult Living Donor Liver Transplantation Cohort Study2 (A2ALL-2). Am J Transplant. 2017 May; 17(5):1267-1277.
  16. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017 Mar; 65(3):804-812.
  17. Levitsky J, Verna EC, O'Leary JG, Bzowej NH, Moonka DK, Hyland RH, Arterburn S, Dvory-Sobol H, Brainard DM, McHutchison JG, Terrault NA. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients. N Engl J Med. 2016 11 24; 375(21):2106-2108.
  18. Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database. Aliment Pharmacol Ther. 2017 Jan; 45(1):115-126.
  19. Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat BE. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology. 2017 Jan; 65(1):65-77.
  20. Terrault NA, Hassanein TI. Management of the patient with SVR. J Hepatol. 2016 Oct; 65(1 Suppl):S120-9.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.